This meta-analysis evaluated whether adjunctive cannabinoids reduce opioid need of cancer patients while preserving optimal pain control, including analyses across total daily opioid dose, maintenance opioid dose, and breakthrough opioid use. Overall, cannabinoids were associated with limited benefits in cancer population, without consistent evidence of reduced opioid requirements. Across outcomes, effects on total, maintenance, and breakthrough opioid use were largely neutral, and findings were characterized by substantial variability and inconsistency, indicating that cannabinoids do not provide a reliable opioid-sparing advantage in cancer pain management.

Overall opioid consumption and the need for breakthrough analgesia remained largely unchanged, indicating that cannabinoids do not substantially modify background opioid exposure or episodic pain requiring rescue medication. Although modest reductions in opioid use were observed in selected settings, most notably for maintenance dosing and primarily with THC-based interventions, these effects were variable, formulation dependent, and not consistently reproduced across studies. Taken together, the findings suggest that any apparent opioid-sparing effects of cannabinoids are limited, heterogeneous, and context dependent, and do not support a robust or generalizable reduction in opioid use in cancer pain management.

However, opioid-sparing effect remains mechanistically plausible because endocannabinoid signaling intersects with central nociceptive modulation and may influence affective pain processing, sleep disruption, anxiety, and symptom appraisal [35]. However, cancer pain in opioid-treated populations is not a static phenotype: pain intensity and opioid requirements fluctuate with tumor progression, inflammatory burden, anticancer therapy, infections, and functional decline [36]. In advanced cancer, clinical priorities commonly emphasize comfort and stability over opioid minimization, and opioid titration is constrained by clinical urgency, adverse effects, and care setting [21]. Consequently, even if cannabinoids provide modest symptom benefit, such improvements may not translate into intentional opioid tapering, particularly within the short follow-up windows typical of cannabinoid RCTs. This clinical context plausibly contributes to the consistently null placebo-controlled effects for total dose and breakthrough opioid use, which integrate multiple downstream processes (opioid titration decisions, rescue policies, intercurrent therapies, and disease trajectory) that can dilute small treatment signals.

Importantly, several RCTs constrained the opioid dosing of the enrolled patients by protocol [19, 20, 25, 34]. Background opioid doses were commonly required to remain stable throughout follow-up, and breakthrough opioid use was restricted by predefined limits, with excessive rescue use sometimes leading to patient exclusion. Under these conditions, potential cannabinoid-related benefits may have been attenuated or masked in opioid-consumption outcomes, since reductions in opioid requirements could not always be captured by trial design. In consequence, the neutral opioid-consumption findings may reflect, at least in part, restricted opportunity for opioid dose modification rather than the complete absence of cannabinoid-related clinical benefit.

The divergence between placebo-controlled comparisons and change-from-baseline analyses is methodologically expected and clinically informative. Baseline-change designs are intrinsically susceptible to regression to the mean, especially when patients enroll during high-symptom periods; subsequent improvement may occur independently of the intervention [37]. Expectancy effects may further contribute, as cannabinoids are associated with strong patient beliefs regarding analgesia and opioid substitution, potentially influencing self-management behaviors and symptom reporting; however, such effects are attenuated in blinded placebo-controlled trials [38]. In addition, opioid titration rules vary across studies, and permissive titration can generate large within-person opioid changes that are not attributable to treatment, inflating heterogeneity in baseline analyses and potentially contributing to the apparent THC-predominant signal in maintenance dosing. Finally, dose-limiting adverse effects may cap cannabinoid exposure, preventing consistent pharmacologic effects across trials and yielding small, inconsistent signals that do not persist under placebo control.

Cannabinoids are often associated with benefits for symptom palliation beyond analgesia. A recent systematic review and meta-analysis conducted by our group synthesized a broad evidence base and reported that cannabinoids were associated with improvements in pain and anxiety compared with baseline values [8]. Importantly, this review also emphasized safety trade-offs, particularly with THC-predominant formulations, reporting increased risks of psychiatric and neurological adverse effects [8]. These harms are clinically silent in opioid-treated cancer patients, who frequently have baseline vulnerability to sedation, cognitive impairment, delirium, falls, and polypharmacy interactions [39]. Moreover, tolerability constraints may limit cannabinoid dose escalation and thereby constrain any potential analgesic or opioid-sparing effects in practice. These opioid-focused findings help contextualize symptom-level results, indicating that while cannabinoids may be associated with within-patient improvements in pain or anxiety in uncontrolled analyses, such improvements do not consistently translate into reductions in opioid use under blinded conditions and may be limited by tolerability and adverse effects.

Clinically, opioid-sparing should not be pursued as an isolated objective in cancer pain management. In advanced cancer and end-of-life care, adequate symptom relief and quality of life remain the primary goals, and appropriately prescribed opioids continue to have a central role [40, 41]. Therefore, adjunctive cannabinoids should not be introduced solely to reduce opioid dose, particularly given their own adverse-effect profile, as previously mentioned. Any opioid-sparing strategy should be considered clinically meaningful only if it reduces opioid exposure without worsening pain control, function, quality of life, or safety.

Our study’s findings are broadly aligned with prior systematic reviews and meta-analyses evaluating cannabinoids in cancer-related pain, particularly in underscoring that effects observed in uncontrolled or baseline-based analyses are often attenuated in placebo-controlled settings. Reviews focused specifically on cancer pain and have generally reported limited or uncertain analgesic benefit when cannabinoids are added to opioid therapy in rigorously controlled trials, suggesting that meaningful downstream reductions in opioid use are unlikely. In this context, the Cochrane review of cannabis-based medicines for adults with cancer pain emphasized both the low certainty of efficacy and the relevance of adverse effects, a pattern that is consistent with the absence of robust opioid-sparing effects observed across total, maintenance, and breakthrough opioid outcomes in controlled analyses [9].

Similar discrepancies between uncontrolled and randomized evidence have been described in broader chronic pain populations receiving prescribed opioids, where observational studies more frequently report reductions in opioid use, while randomized trials yield smaller, inconsistent, or null effects and are limited by substantial confounding. The article conducted by Noori et al.reflects a comparable structure within opioid-treated cancer pain, in which modest baseline changes, most apparent for maintenance dosing and largely confined to THC-based interventions, are not consistently reproduced in controlled comparisons [10]. The same trend was emphasized by Nielsen et al.where the analysis found no consistent evidence of opioid reduction in randomized controlled trials, despite more favorable signals in uncontrolled or observational data [42]

A key strength of this review is its focused assessment of opioid-sparing in opioid-treated cancer patients, distinguishing it from broader reviews of cannabinoids for cancer pain or chronic pain. We separately analyzed total opioid consumption, maintenance/background opioid dose, and breakthrough/rescue opioid use, rather than treating opioid use as a single outcome. We also distinguished placebo-controlled effects from within-group baseline changes, improving causal interpretation while contextualizing opioid trajectories over time. Also, subgrouping by cannabinoid formulation increased clinical interpretability given expected differences in efficacy and tolerability across THC-predominant, balanced THC:CBD, and CBD-predominant products.

The main limitations of this review reflect the nature of the available evidence, which is both heterogeneous and only partly aligned with the clinical question of opioid-sparing. From a clinical perspective, opioid-sparing requires more than a numerical reduction in opioid dose; it implies a sustained decrease in opioid exposure without deterioration in pain control, function, quality of life, or safety [43]. Most available studies were not designed around this composite clinical objective; instead, opioid consumption was often captured as a secondary or exploratory measure within trials primarily evaluating analgesic efficacy, symptom control, or tolerability.

This creates several interpretive challenges. First, opioid outcomes are highly dependent on protocol conditions, including baseline opioid optimization, allowing dose adjustments, rescue medication rules, tapering procedures, and follow-up duration. If opioid dosing is kept stable or rescue use is capped, a potential symptomatic benefit may not translate into measurable opioid reduction. Conversely, in uncontrolled studies, reductions in opioid use may reflect disease trajectory, regression to the mean, patient preference, clinician behavior, or expectancy effects rather than a true pharmacologic opioid-sparing effect. Second, the included populations vary widely in cancer type, disease stage, prognosis, baseline opioid exposure, and palliative care context, all of which influence whether opioid reduction is clinically appropriate or feasible. Third, cannabinoid interventions differ substantially in formulation, THC:CBD ratio, dose, route of administration, titration schedule, and tolerability profile, limiting the ability to identify whether any opioid-sparing signal is formulation-specific or patient-specific.

Patient-level variability represents another important source of uncertainty in opioid-specific outcomes. Opioid requirements in cancer pain are influenced not only by pain intensity, but also by duration of prior opioid therapy, opioid tolerance, cancer diagnosis and stage, pain mechanism, performance status, renal and hepatic function, concomitant analgesics or sedating medications, and exposure to anticancer treatments [44]. In addition, inter-individual differences in opioid pharmacokinetics and pharmacodynamics, including genetic variability affecting opioid metabolism and receptor sensitivity, may contribute to substantial variation in the dose required to achieve adequate analgesia [45]. These factors may obscure cannabinoid-related effects if they are not measured, balanced, or adjusted for in trial analyses.

These gaps have direct implications for clinical practice: the available evidence does not allow clinicians to reliably identify which patients, if any, are likely to reduce opioid requirements with cannabinoids, nor under what dosing strategy this could be achieved safely. Future research should therefore move from simply recording opioid consumption toward prospectively testing opioid-sparing strategies. Trials should define opioid reduction as a primary or key secondary endpoint, use standardized morphine-equivalent reporting, distinguish maintenance from breakthrough opioid use, incorporate prespecified tapering or opioid-adjustment algorithms, and evaluate whether opioid reductions occur without worsening pain, function, sleep, psychological distress, or adverse-event burden. RCTs and high-quality observational studies may also be useful, provided they carefully control baseline opioid dose, disease progression, anticancer treatment, performance status, and palliative care involvement. Such designs would better determine whether cannabinoids have a clinically meaningful opioid-sparing role, rather than merely showing whether opioid use changes over time. Until such evidence is available, cannabinoids should be viewed as potential adjunctive symptom-directed therapies rather than established opioid-sparing interventions in cancer pain management.